Robert E. Landry - 12 Dec 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role: EVP Finance CFO
Signature: /s/**Robert E. Landry
Issuer symbol: REGN
Transactions as of: 12 Dec 2023
Net transactions value: -$5,717,506
Form type: 4
Filing time: 14 Dec 2023, 16:08:07 UTC
Previous filing: 12 Dec 2023
Next filing: 29 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Tax liability	$5,466,667	-6,381	-23%	$856.71	21,084	12 Dec 2023	Direct
transaction	REGN	Common Stock	Options Exercise	$378,980	+1,000	+4.7%	$378.98	22,084	13 Dec 2023	Direct
transaction	REGN	Common Stock	Tax liability	$629,820	-723	-3.3%	$871.12	21,361	13 Dec 2023	Direct
holding	REGN	Common Stock						270	12 Dec 2023	By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-1,000	-4.9%	$0.000000	19,337	13 Dec 2023	Common Stock	1,000	$378.98	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option award vests in four equal annual installments, commencing one year after the date of grant.